Top Tweets for #foundayo
https://t.co/Xgpobgba9l Big news in Canada this week – orforglipron (#Foundayo) is now approved as our first GLP1 pill for weight management! Find out more about it here.
Eli Lilly’s Foundayo weight loss pill receives TGA approval in Australia and is expected to hit pharmacies soon, expanding oral GLP-1 treatment options.
Read More-https://t.co/4JJgH6AX1q
#Foundayo #EliLilly #WeightLoss #GLP1 #HealthcareNews

#EliLilly to present new data across #Zepbound, #Foundayo, #EloraTZP and #retatrutide at #ObesityWeek 2026, moving #obesity care beyond the scale
https://t.co/VZtF9avzoX

في اليوم العالمي للسكري، نؤكد أهمية الكشف المبكر والوقاية.
الإمارات تعتمد دواء Foundayo لعلاج السكري من النوع الثاني، بخطوة تعكس تقدم الابتكار الطبي وتحسين جودة حياة المرضى.
#اليوم_العالمي_للسكري #الإمارات #Foundayo
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China
#Foundayo I #China I #Approval I #GLP_1 I #Weight_loss I #Oral_pill I @EliLillyandCo
Read more:
https://t.co/owo3mnV7LF
The fear mongering about #Glp1s and #VisionLoss is much more dangerous than any side effects from the drugs #glp1 #Ozempic #Wegovy #Semaglutide #Zepbound #Mounjaro #Tirzepatide #orforglipron #Foundayo #Muyouda

#EliLilly becomes first drugmaker to have a #GLP1 weight loss pill approved in China #orforglipron #Foundayo $lly
https://t.co/jdcEt2a53O
⚖️ @EliLillyandCo Highlights Foundayo in New Weight Health Campaigns
@EliLillyandCo spotlights Foundayo in new campaigns focused on weight health and treatment awareness.
🔗 https://t.co/7lWb9x4fR3
#Lilly #Foundayo #WeightHealth #Pharma

$LLY's oral #Foundayo (#orforglipron) cut sleep apnea AHI events by up to 43.8% at 52 weeks in Phase 3 ATTAIN-OSA, alongside ~11.5% #weightloss and lower hsCRP & blood pressure
https://t.co/B2HRIVS4ry
#AHA26 #AHA2026 #OSA #Pharma
Emirates Drug Establishment approves Eli Lilly's Foundayo for adults with type 2 diabetes, becoming the third country to authorize the treatment.
https://t.co/t0wr6jakB2
#EmiratesDrugEstablishment #EDE #Foundayo #FoundayoOrforglipron #Orforglipron #GCCBusinessNews
@EDE_UAE

🟢ا $LLY
🔸ا Eli Lilly
حصلت على رأي إيجابي من لجنة المنتجات الطبية
للاستخدام البشري التابعة لوكالة الأدوية الأوروبية،
يوصي بمنح ترخيص تسويق لدواء #Foundayo لعلاج
داء السكري من النوع الثاني ولإدارة الوزن
تتداول قبل الافتتاح عند 1258$
🔸ا #الأسهم_الأمريكية

$LLY Eli Lilly’s Foundayo: 64.2K → 57.9K weekly scripts (-9.8%), reportedly.
Heavy marketing, discounts and free samples can drive trials. But are patients staying and refilling? That matters more than a launch spike.
$NVO’s Wegovy pill still leads oral scripts. #Foundayo

🇩🇰 Oral GLP-1 momentum is back! 📈
Latest #IQVIA data: Novo’s #Wegovy pill prescriptions surged 14.3% WoW, from 161K to 184K — a new high. Lilly’s #Foundayo also climbed 13.4%, from 47K to 53.3K.
Last week’s holiday disrupted prescription volumes. With a full trading week, both treatments rebounded strongly.
The key takeaway for $NVO: Wegovy’s pill continues to demonstrate substantial demand, while the oral GLP-1 market is expanding rapidly. The competition is growing — but so is the opportunity.
Source: Fierce Pharma $LLY

Eli Lilly CEO reports one-third of new GLP-1 patients use Foundayo as production ramps up. Medicare coverage drives demand for obesity treatments.
https://t.co/yK0bynfyat
#EliLilly #Foundayo #GLP1Drugs #Pharmaceuticals #DrugMarket

Europe's first weight-loss pill you can take without food or water rules: Eli Lilly's oral weight-loss drug Foundayo just launched in the U.K., giving British patients a cheaper alternative to injectable options like Mounjaro — at… https://t.co/duT3BtWqZz #WeightLoss #Foundayo

اعتمدت #الغذاء_والدواء
مطلع هذا الشهر تسجيل دواء #فاوندايو #Foundayo
كخيار علاجي للسمنة.
💊وتعتبر أول حبوب سمنة بالإمكان تناولها في أي وقت دون التقيد بوقت محدد من تناول الطعام👌
💊وتصل نسبة فعالية فقدان الوزن إلى 11% تقريبًا.

💥تطور جديد في علاج #السمنة💥
#الغذاء_والدواء الأمريكية تعتمد
دواء (حبوب ) #أورفورغليبرون
(#فوندياو) 🔴🔴
لتصبح أول حبوب صغيرة الجزيء
من فئة (ناهضات GLP-1) ومعتمدة
لعلاج #السمنة🔴
تؤخذ مرة واحدة يوميًا،دون
الحاجة للتقيد بوقت الطعام🔴
لمعرفة المزيد
👇

Orforglipron is an investigational oral GLP-1 receptor agonist being studied for weight management and type 2 diabetes. Its once-daily oral format may offer a convenient alternative to injectable GLP-1 therapies.
For informational purposes only.
#Orforglipron #Foundayo #GLP1

Last Seen Hashtags on Sotwe
twink
肌肉奴
Seen from Japan
agegap #ageplay(**********************************)**filter:videos
Seen from United Arab Emirates
bnwo little sis
Seen from Turkey
habeshasex
فطافيط
Seen from Canada
liseliporno
Seen from Turkey
señora(((())))***+filter:native_video
Seen from Mexico
巧虎
Seen from Guatemala
nolimit #teenage #brother
Seen from United States
Trends for you
Most Popular Users

Elon Musk 
@elonmusk
240.5M followers

Barack Obama 
@barackobama
118.7M followers

Cristiano Ronaldo 
@cristiano
114.4M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.4M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.7M followers

Neymar Jr 
@neymarjr
66.4M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63M followers

The Ellen Show
@theellenshow
62.1M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers

















